ViiV Healthcare’s Rukobia received EMA marketing authorisation
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc and Shionogi Limited as shareholders, announced... Read More
CoronaVac received conditional marketing authorization from NMPA China
Posted on10 Feb 2021
Comments0
Sinovac Biotech announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac,... Read More
Myovant and Pfizer’s $4.2 Billion Deal for Orgovyx
Myovant Sciences is partnering with Pfizer to develop and commercialize Orgovyx for prostate cancer and women’s health. Orgovyx is the brand of... Read More
Telix Pharma to acquire TheraPharm GmbH
Telix Pharmaceuticals announced that it has entered into an agreement with Scintec Diagnostics GmbH (Scintec) to acquire TheraPharm GmbH, a Swiss-German biotechnology... Read More
Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development
Posted on28 Nov 2020
Comments0
More than 50 covid-19 vaccine candidate is currently under development. Here you can have the close look into the development status of... Read More
PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
Posted on28 Nov 2020
Comments0
Biotechnology company PostEra announced a collaboration with NeuroLucent, a Chicago-based company focused on developing novel treatments for Alzheimer’s disease and other dementias.... Read More
Pfizer submitted application for emergency use of Covid vaccine
US drugmaker Pfizer Inc, which has developed a vaccine against coronavirus, is now seeking the emergency use tag from the US government... Read More
Understanding on India’s Revised Patent Rules On Priority filing w.e.f 19 October, 2020
The Indian Patent office has issued a notification that the Patents (Amendment) Rules, 2020, was released and enforced on 19 October, 2020.... Read More
Insight of BioInvent’s licensing deal of anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region. BioInvent have entered into an exclusive licensing agreement for the... Read More
Insight on Veklury’s clinical and strategic pathway for USFDA approval for Covid-19
Posted on24 Oct 2020
TagsCOVID-19, priority review, Priority Review Designation, Remdesivir, usfda, usfda accelerated approval, USFDA Priority Review, Veklury
Comments0
USFDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at... Read More